Correspondence | Published:

Assessing unintended hybridization-induced biological effects of oligonucleotides

Nature Biotechnology volume 30, pages 920923 (2012) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Proc. Natl. Acad. Sci. USA 75, 280–284 (1978).

  2. 2.

    et al. Nature 391, 806–811 (1998).

  3. 3.

    et al. Toxicologic properties of 2′-methoxyethyl chimeric antisense inhibitors in animals and man. in Antisense Drug Technology: Principles Strategies, and Applications. (ed. Crooke, S.T.) 327–364 (CRC Press, 2007).

  4. 4.

    & Biochemistry 40, 4980–4989 (2001).

  5. 5.

    & Annu. Rev. Pharmacol. Toxicol. 50, 259–293 (2010).

  6. 6.

    et al. RNA 15, 308–315 (2009).

  7. 7.

    et al. RNA 12, 1179–1187 (2006).

  8. 8.

    & Biochem. Biophys. Res. Commun. 319, 256–263 (2004).

  9. 9.

    et al. Nat. Biotechnol. 21, 635–637 (2003).

  10. 10.

    et al. PLoS Genet. 2, e140 (2006).

  11. 11.

    et al. Nat. Genet. 43, 371–378 (2011).

Download references

Author information

Affiliations

  1. Santaris Pharma A/S, Hørsholm, Denmark.

    • Morten Lindow
  2. Axolabs GmbH, Kulmbach, Germany.

    • Hans-Peter Vornlocher
  3. DNA Consulting LLC, Ellensburg, Washington, USA.

    • Donald Riley
  4. Preclinsight, Reno, Nevada, USA.

    • Douglas J Kornbrust
  5. Merck & Co., Inc., West Point, Pennsylvania, USA.

    • Julja Burchard
  6. Pfizer, Cambridge, Massachusetts, USA.

    • Laurence O Whiteley
  7. RXi, Worcester, Massachusetts, USA.

    • Joanne Kamens
  8. Quark Pharmaceuticals, Boulder, Colorado, USA.

    • James D Thompson
  9. Alnylam Therapeutics, Cambridge, Massachusetts, USA.

    • Saraswathy Nochur
  10. Isis Pharmaceuticals, Carlsbad, California, USA.

    • Husam Younis
    •  & Scott P Henry
  11. Merck & Co., Inc., Palo Alto, California, USA.

    • Steven Bartz
  12. GlaxoSmithKline R&D, Ware, Hertfordshire, UK.

    • Joel Parry
  13. Topigen Pharmaceuticals, Pharmaxis Ltd., Montreal, Quebec, Canada.

    • Nicolay Ferrari
  14. miRagen Therapeutics, Boulder, Colorado, USA.

    • Arthur A Levin

Authors

  1. Search for Morten Lindow in:

  2. Search for Hans-Peter Vornlocher in:

  3. Search for Donald Riley in:

  4. Search for Douglas J Kornbrust in:

  5. Search for Julja Burchard in:

  6. Search for Laurence O Whiteley in:

  7. Search for Joanne Kamens in:

  8. Search for James D Thompson in:

  9. Search for Saraswathy Nochur in:

  10. Search for Husam Younis in:

  11. Search for Steven Bartz in:

  12. Search for Joel Parry in:

  13. Search for Nicolay Ferrari in:

  14. Search for Scott P Henry in:

  15. Search for Arthur A Levin in:

Competing interests

The authors are employees in, or consultants for, commercial companies actively developing oligonucleotides as drugs. See affiliation section for details.

Corresponding author

Correspondence to Arthur A Levin.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2376

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing